Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07455903 · ClinicalTrials.gov registry record · Phase 2
Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT
A Phase 2 study, sponsored by Baptist Health South Florida.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT07455903 is a Phase 2 study that is actively recruiting participants, run by Baptist Health South Florida. The registered enrollment target is 50 participants.
The verdict
NCT07455903, a Phase 2 study, is actively recruiting participants, sponsored by Baptist Health South Florida.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
The purpose of this research study is to test the efficacy of ADT on prostate-specific membrane antigen (PSMA), a marker of prostate cancer, before and after scheduled ADT. Follow up will be 48 months your prostate removal to do a blood test and log if any new or worsening symptoms have occurred as a part of your standard-of-care (SOC).
Interventions
- DRUG Relugolix
- DRUG Bicalutamide
- DRUG Degarelix
- DRUG Leuprolide
- DRUG Triptorelin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2026-04-23 |
| Est. Completion | 2030-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07455903
The ClinicalTrials.gov registry entry for NCT07455903 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baptist Health South Florida, which has 40 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Relugolix is the first listed.
NCT07455903 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07455903 about?
NCT07455903 is a clinical study titled "Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT". The purpose of this research study is to test the efficacy of ADT on prostate-specific membrane antigen (PSMA), a marker of prostate cancer, before and after scheduled ADT. Follow up will be 48 months your prostate removal to do a blood test and log if any new or worsening symptoms have occurred as ...
What is the current status of trial NCT07455903?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2026-04-23. Estimated completion is 2030-10.
What interventions are being tested in trial NCT07455903?
The interventions under investigation include: Relugolix (DRUG), Bicalutamide (DRUG), Degarelix (DRUG), Leuprolide (DRUG), Triptorelin (DRUG).
Who is sponsoring clinical trial NCT07455903?
This trial is sponsored by Baptist Health South Florida, which has 40 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.